TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9525444
Drug: Fexofenadine 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 240 mg single dose
Study: 8749149
Drug: Clemastine 2
Normalized name: clemastine 2 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine 2 mg twice daily
Study: 7848623
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug therapy (one of five active drugs)
Study: 7848623
Drug: Nutritional‐hygienic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional‐hygienic therapy and active drugs
Study: 2595644
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravenous PK 11195
Study: 4590668
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate aerosol at a dosage of 400 to 800 mug/day for three months
Study: 4590668
Drug: Steroid aerosols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid aerosols (betamethasone valerate or beclomethasone dipropionate) at a daily maintenance dose of 200 mug/day
Study: 4590668
Drug: Steroid aerosols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid aerosols (betamethasone valerate or beclomethasone dipropionate)
Study: 25683592
Drug: Prednisolone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (0.5 mg kg(-1) daily)
Study: 23533302
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract (AGE) 1.2 g/day for 12 weeks
Study: 22134936
Drug: video capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: video capsule endoscopy (VCE)
Study: 16798758
Drug: Ramp ATP
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramp ATP therapy
Study: 16627459
Drug: Burst+ ATP
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Burst+ ATP therapy
Study: 9048271
Drug: Delayed-release oral
Normalized name: Prevacid 1 MG/ML Delayed-Release Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release oral azathioprine 200 mg
Study: 9048271
Drug: Delayed-release oral
Normalized name: Prevacid 1 MG/ML Delayed-Release Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release oral azathioprine 400 mg
Study: 9048271
Drug: Delayed-release oral
Normalized name: Prevacid 1 MG/ML Delayed-Release Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release oral azathioprine 600 mg
Study: 9048271
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral azathioprine 100 mg (control)
Study: 8104966
Drug: Azelastine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 4 mg every 12 hours
Study: 8104966
Drug: Azelastine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 8 mg every 12 hours
Study: 8104966
Drug: Chlorpheniramine 12
Normalized name: Chlorpheniramine 12 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine 12 mg every 12 hours
Study: 8104966
Drug: Azelastine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine (both doses)
Study: 3535933
Drug: L-PAM plus
Normalized name: L-PAM
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-PAM plus 5-FU (PF)
Study: 3535933
Drug: Nuclear grade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuclear grade in combination with either or both of the receptors
Study: 30063470
Drug: Alemtuzumab as
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab as a conditioning agent
Study: 27334138
Drug: n-3 LCPUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 LCPUFAs (722 mg DHA)
Study: 27334138
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (2000 IU) + n-3 LCPUFAs (722 mg DHA)
Study: 22691894
Drug: Fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 4 mg for 6 days
Study: 22691894
Drug: Fesoterodine 8
Normalized name: fesoterodine 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 8 mg for 3 days after 4 mg for 3 days
Study: 22691894
Drug: Alprazolam 1
Normalized name: alprazolam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 1 mg on day 6
Study: 18842795
Drug: Zinc (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (20 mg as sulfate) and micronutrients 5 d/wk for 10 wk
Study: 12192466
Drug: Intravenous citalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous citalopram
Study: 8540873
Drug: salbutamol 1
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: salbutamol 1 mg in 2 mL saline via jet nebuliser
Study: 7148373
Drug: Incentive spirometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive spirometry combined with chest physical therapy
Study: 7148373
Drug: Chest physical
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest physical therapy alone
Study: 25039260
Drug: Eight self-administered
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight self-administered weekly treatments with an 810-nm home-use laser at 5.0-6.4 J cm(‐2)
Study: 25039260
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (zero treatments)
Study: 23432535
Drug: Diltiazem supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem supplement
Study: 23432535
Drug: Routine doses
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine doses of tacrolimus (Control)
Study: 23432535
Drug: CYP3A5 polymorphism-guided
Normalized name: ANGELICA POLYMORPHA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP3A5 polymorphism-guided dosing equation
Study: 21226883
Drug: Smoking reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking reduction counselling plus free nicotine replacement therapy (NRT)
Study: 15625361
Drug: Somatostatin receptor
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin receptor scintigraphy (SRS)
Study: 9727686
Drug: Conversion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conversion therapy (amiodarone for restoration and maintenance of sinus rhythm)
Study: 9727686
Drug: Control of
Normalized name: A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control of ventricular rate only (diltiazem as primary therapy)
Study: 8535958
Drug: 0.3% ofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% ofloxacin ophthalmic ointment
Study: 8535958
Drug: 0.3% ofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% ofloxacin ophthalmic solution
Study: 2403734
Drug: Low-dose sotalol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sotalol (160 mg administered twice daily)
Study: 2403734
Drug: High-dose sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sotalol (320 mg administered twice daily)
Study: 721790
Drug: Doxepin (112.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (112.7 mg/day)
Study: 721790
Drug: Imipramine (116.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (116.7 mg/day)
Study: 17392726
Drug: Methylnaltrexone 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylnaltrexone 0.3 mg/kg
Study: 17216322
Drug: High spinal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High spinal anesthesia (2.7 ml of 0.5% hyperbaric bupivacaine)
Study: 17216322
Drug: Low spinal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low spinal anesthesia (1.5 ml of 0.5% hyperbaric bupivacaine)
Study: 31091508
Drug: Ketorolac (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (30 mg)
Study: 15577367
Drug: Bupivacaine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (150 mg)
Study: 15577367
Drug: Ketorolac (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (30 mg) and Bupivacaine (150 mg)
Study: 9235679
Drug: Thromboprophylaxis (dextran‐70,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thromboprophylaxis (dextran‐70, low molecular weight heparin, and graded elastic stockings) during the first week after operation
Study: 28763548
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (0.6-0.8 mg/kg/d; maximum 48 mg/d) for 2 months, followed by weaning over 4 to 6 months.
Study: 25618178
Drug: Ovarian hyperstimulation
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian hyperstimulation with FSH + insemination + metformin
Study: 14659529
Drug: Baseline psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline psychological measures during drug-free period
Study: 10759689
Drug: Reviparin (s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reviparin (s.c. injection of 6300 anti-Xa units)
Study: 10759689
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA 300 mg o.d. from day 1-5)
Study: 10759689
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of reviparin and ASA
Study: 10759689
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA 300 mg)
Study: 10759689
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with ASA and reviparin
Study: 20671623
Drug: S-adenosyl-L-methionine (SAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (SAM)
Study: 30635887
Drug: Daily single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily single-dose triple therapy (esomeprazole 40 mg, tinidazole 1 g, levofloxacin 500 mg once-daily for 14 days)
Study: 30635887
Drug: Conventional triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional triple therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg twice-daily for 14 days)
Study: 30635887
Drug: Daily single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily single-dose triple therapy
Study: 30635887
Drug: Conventional triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional triple therapy
Study: 27233377
Drug: Continuous alternating
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous alternating therapy (CAT) with inhaled aztreonam (AZLI) and tobramycin inhalation solution (TIS)
Study: 19968808
Drug: Remifentanil bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil bolus dose (3.1 mcg x kg(‐1) for group I, 3.7 mcg x kg(‐1) for group II, 3.0 mcg x kg(‐1) for group III)
Study: 19968808
Drug: Remifentanil bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil bolus dose (3.1-3.7 mcg x kg(‐1))
Study: 1614047
Drug: 1.36% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.36% glucose solution
Study: 11920355
Drug: 2.27% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.27% glucose solution
Study: 1614047
Drug: 3.86% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.86% glucose solution
Study: 1614047
Drug: All glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: All glucose solutions (1.36%, 2.27%, 3.86%)
Study: 29112514
Drug: Intravenous cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cold saline (CS) (4°C)
Study: 29112514
Drug: Intravenous room
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous room temperature saline (RS) (22°C)
Study: 24265104
Drug: Cortisol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (20 mg) administered 1 hr before therapy sessions
Study: 24265104
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 1 hr before therapy sessions
Study: 22210231
Drug: Inhalation group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation group (sevoflurane-N2O)
Study: 20563735
Drug: Topical tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tramadol (2 mg/kg diluted in 10 ml saline)
Study: 20563735
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 ml saline)
Study: 11339443
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (0.5-5 mg daily)
Study: 11339443
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 (mean 0.5 mg daily)
Study: 11339443
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 (mean 16.5 mg daily)
Study: 9347206
Drug: Oral triphasic
Normalized name: Tribasic Calcium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral triphasic contraceptive steroids (ethinyl estradiol and levonorgestrel)
Study: 8137343
Drug: Chronic low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic low dose etoposide administration (21 days)
Study: 8137343
Drug: Frequent weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Frequent weekly or twice weekly administration of larger intravenous doses
Study: 8137343
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of active intracellular drug concentrations
Study: 3533811
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms L‐triiodothyronine
Study: 30572991
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (1,500-2,000 IU daily)
Study: 30572991
Drug: Non-intervention (Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-intervention (Insulin treatment only)
Study: 26954945
Drug: Fractionated coconut
Normalized name: Fractionated coconut oil
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated coconut oil 1.0 mL infused in the uterus on Day 10 (Group 1; n = 5)
Study: 26954945
Drug: Fractionated coconut
Normalized name: Fractionated coconut oil
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated coconut oil 0.5 mL infused in the uterus on Day 10 (Group 2; n = 5)
Study: 23252201
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of cefoxitin
Study: 23252201
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml of vitamin B complex intravenously
Study: 19927027
Drug: 35% protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% protein (approximately 2.3 g x kg(‐1))
Study: 19927027
Drug: 15% protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% protein (approximately 1.0 g x kg(‐1))
Study: 18700714
Drug: Abhay M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abhay M vaccine
Study: 18700714
Drug: M-Vac vaccine
Normalized name: M-2698
DrugBank: M-2698 (DB15431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-Vac vaccine
Study: 10392981
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg acetylsalicylic acid daily
Study: 10392981
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg acetylsalicylic acid daily
Study: 10392981
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg acetylsalicylic acid daily
Study: 10392981
Drug: 1300 mg
Normalized name: gelatin 1300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1300 mg acetylsalicylic acid daily
Study: 10392981
Drug: Efficacy analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efficacy analysis excluding patients taking 650 mg or more acetylsalicylic acid
Study: 2066454
Drug: Adinazolam (60-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam (60-90 mg/day)
Study: 2066454
Drug: Amitriptyline (150-225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (150-225 mg/day)
Study: 2066454
Drug: Diazepam (30-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (30-45 mg/day)
Study: 28122361
Drug: Non-antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-antiviral therapy
Study: 26406981
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing cinnamon, chromium and carnosine (1.2 g/day)
Study: 21269484
Drug: EPO therapy
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO therapy (5,000 IU subcutaneously at 48 h and 72 h after acute IS)
Study: 21269484
Drug: EPO therapy
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO therapy (group 1)
Study: 10395851
Drug: Atovaquone 750
Normalized name: ATOVAQUONE 750MG/5ML SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone 750 mg once a day
Study: 10395851
Drug: Atovaquone 1500
Normalized name: ATOVAQUONE 1500 mg in 10 mL ORAL SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone 1500 mg once a day
Study: 10395851
Drug: Aerosolized pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine 300 mg once a month
Study: 8847035
Drug: Octreotide 100
Normalized name: 1 ML octreotide 100 MCG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 100 mcg bolus intravenously followed by 25 mcg/h intravenously for 1.4 +/- 0.6 days
Study: 8847035
Drug: Ranitidine 100
Normalized name: ranitidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 100 mg intravenously every 12 h
Study: 6896575
Drug: Isaxonine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isaxonine (4 capsules of 375 mg daily)
Study: 6896575
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 capsules filled with lactose)
Study: 27606613
Drug: 1500 ml
Normalized name: Bag/Pump Set 1500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 ml of oral rehydration solution (rehydration group)
Study: 25963302
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg pemirolast
Study: 25963302
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg pemirolast
Study: 25963302
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pemirolast
Study: 17984344
Drug: Human and
Normalized name: cultured skin substitute,human and bovine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human and bovine praziquantel treatment
Study: 17984344
Drug: Human praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human praziquantel treatment only
Study: 15119493
Drug: Benzodiazepine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine treatment program
Study: 15119493
Drug: Observation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation with CIWA-Ar administered every eight hours for 48 hours
Study: 8178407
Drug: BCG Connaught
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG Connaught 120 mg
Study: 2906556
Drug: L-tyrosine 50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tyrosine 50, 250 and 500 mg kg-1
Study: 2906556
Drug: L-tyrosine 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tyrosine 250 and 500 mg kg-1 with idazoxan (0.1 mg kg-1 i.v.)
Study: 2906556
Drug: Idazoxan (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (0.1 mg kg-1 i.v.)
Study: 29921320
Drug: Navoximod (GDC-0919)
Normalized name: calcium carbonate
DrugBank: Navoximod (DB15439)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Navoximod (GDC-0919) administered at doses of 50-800 mg BID on a 21/28 day schedule and 600 mg on a 28/28 day schedule
Study: 25284751
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng (KRG) 500 mg, six capsules twice daily for 8 weeks
Study: 24321164
Drug: Acetyl-L-carnitine (ALCAR)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALCAR) 2g
Study: 18538054
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL 0.25% levobupivacaine
Study: 18538054
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL saline placebo (control group)
Study: 9562227
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (250 ml)
Study: 7717487
Drug: Thiopentone (step
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (step 1: 1.25 mg.kg‐1 followed by 2.5 mg.kg‐1.h‐1; step 2: 1.25 mg.kg‐1 and 12.5 mg.kg‐1.h‐1; n = 15)
Study: 7717487
Drug: Propofol (step
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (step 1: 0.5 mg.kg‐1, 1 mg.kg‐1.h‐1; step 2: 0.5 mg.kg‐1, 5 mg.kg‐1.h‐1; n = 15)
Study: 6791864
Drug: Penicillin (55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (55 mg/kg/day for 7 days)
Study: 24635935
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between 1000 pulse and 2000 pulse treatment arms
Study: 23754188
Drug: Rilonacept (2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept (2.2 mg/kg or 4.4 mg/kg)
Study: 20804367
Drug: Methyl B12
Normalized name: Methyl vitamin B12
DrugBank: Mecobalamin (DB03614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyl B12 (64.5 mcg/kg every three days for 6 weeks)
Study: 15882144
Drug: Ucn 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ucn 1 infusion (50 microg intravenously over 1 hour)
Study: 12933408
Drug: Droperidol 5
Normalized name: droPERidol 5 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 5 micro g